Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Immunosuppressive therapies, such as alemtuzumab and cyclosporine, may improve
bone marrow function and increase blood cell counts. Giving alemtuzumab together with
cyclosporine may be an effective treatment for severe aplastic anemia or acquired marrow
failure.
PURPOSE: This phase II trial is studying the side effects of giving alemtuzumab together with
cyclosporine and to see how well it works in treating patients with severe aplastic anemia or
acquired marrow failure.